Аntifungal activity of 5-(2-nitrovinyl) imidazoles and their derivatives against the causative agents of vulvovaginal candidiasis

Keywords: nitro containing imidazole derivatives; yeast-like fungi; Candida; clinical strains; antifungal means; anti-Candida action; antimycotic agents


Development of resistance of yeast-like fungi belonging to the Candida genus to the existing antifungal medicines as well as the high toxicity and low tolerance of these medicines in many cases stipulate the acute need for new antibiotic compounds. In this context, an extremely promising group of chemical substances is imidazole derivatives. Therefore, the search for more active and less toxic medical preparations based on imidazole is a relevant and important issue for medical practice. Considering the urgent demand for new antifungal preparations, four new nitro containing imidazole derivatives were synthesized – 5-(2-nitrovinyl) imidazoles and their derivatives. Then in vitro by means of double serial dilution in Saburo liquid nutritious medium we examined their antifungal action against eight clinical strains of yeast-like fungi belonging to the Candida genus: C. albicans, C. guillermondii, C. krusei, С. glabrata, C. kefyr, C. tropicalis, C. inconspicua and C. zeylanoides). They were isolated and identified from the vulvovaginal content of women suffering from vulvovaginal candidiasis. 3-methyl-4-[1-(1-naphthyl-4-chloro-1Н-imidazole-5-yl)-2-nitroethyl-]-1H-pyrazole-5-ole and 2,4-dichloro-5-(2-nitrovinyl)-1-(4-fluorophenyl)-1Н-imidazole were found to be the most active compounds – mean values of minimal fungistatic concentrations of these compounds against all the eight examined strains were 34.9 and 39.7 µg/mL (with the ranges of these concentrations 5.2–83.3 µg/mL) respectively. 2,4-dichloro-3-methyl-4-{2-nitroethyl-1-[1-(4-fluorophenyl)-1Н-imidazole-5-yl]}-1H-pyrazole-5-ole and 1-naphthyl-5-(2-nitrovinyl)-4-chloro-1Н-imidazole were found to possess lower anti-Candida activity – mean values of their minimal fungistatic concentrations against all the eight clinical strains were 48.8 and 51.4 µg/mL (with the ranges of these concentrations 10.4–166.7 µg/mL) respectively. The highest antifungal activity of 5-(2-nitrovinyl) imidazoles and their derivatives was found to be against the clinical strains C. krusei, C. kefyr and C. inconspicua – mean values of minimal fungistatic concentrations concerning the indicated strains were 11.7–26.0 µg/mL. The examined nitro containing imidazole derivatives were found to manifest a slightly lower anti-Candida action against the clinical strains C. tropicalis and C. guilliermondii (mean values of minimal fungistatic concentrations 31.3 and 36.5 µg/mL). The lowest antifungal activity of the examined compounds was detected against the clinical strains C. аlbicans and С. glabrata – mean values of minimal fungistatic concentrations against these strains were 85.9 and 79.4 µg/mL. Comparison of anti-Candida activity of different 5-(2-nitrovinyl) imidazoles and their derivatives enabled us to select their most promising representatives and give recommendations for further synthesis of new nitro containing imidazole derivatives with pronounced antifungal properties.


Castanheira, M., Messer, S. A., Rhomberg, P. R., Dietrich, R. R., Jones, R. N., & Pfaller, M. A. (2014). Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: Application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia, 178(1–2), 1–9.

Chornous, V. O., Melʹnyk, O. Y., Hroza, A. M., Yakovychuk, N. D., & Vovk, M. V. (2014). Syntez ta antymikrobna aktyvnistʹ 4-khloro-5-(2-nitrovinil)-1N-imidazoliv i produktiv yikh vzayemodiyi z 3-metyl-2-pirazolin-5-onom. [Synthesis and antimicrobial activity of 4-chloro-5-(2-nitrovinyl)-1h-imidazoles and products of their interaction with 3-methyl-2-pyrazolin-5-one]. Journal of Organic and Pharmaceutical Chemistry, 47, 28–32 (in Ukrainian).

Gupta, A. K., Jain, A., Mishra, S., & Jiaswal, A. (2012). Design and synthesis of substituted imidazole derivatives as antifungal agents. International Journal of Drug Design and Discovery, 3(4), 943–954.

Hani, U., Shivakumar, H. G., Vaghela, R., Osmani, R. A., & Shrivastava, A. (2015). Candidiasis: A fungal infection-current challenges and progress in prevention and treatment. Infect Disord Drug Targets, 15(1), 42–52.

Jensen, R. H., Hagen, F., Astvad, K. M., Tyron, A., Meis, J. F., & Arendrup, M. C. (2016). Azole-resistant Aspergillus fumigatus in Denmark: A laboratory-based study on resistance mechanisms and genotypes. Clinical Microbiology and Infection, 22(6), 570.

Karabıçak, N., & Alem, N. (2016). Antifungal susceptibility profiles of Candida species to triazole: Application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance. Mikrobiyolоji Bulteni, 50(1), 122–132.

Padmavathi, V., Mahesh, K., Reddy, G. D., & Padmaja, A. (2010). Synthesis and bioassay of pyrrolyl oxazolines and thiazolines. European Journal of Medicinal Chemistry, 45(7), 3178–3183.

Pfaller, M. A. (2012). Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. The American Journal of Medicine, 125(1), 3–13.

Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Jones, R. N., & Castanheira, M. (2013). In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. Journal of Clinical Microbiology, 51(8), 2608–2616.

Posteraro, B., Spanu, T., Fiori, B., De Maio, F., De Carolis, E., Giaquinto, A., Prete, V., De Angelis, G., Torelli, R., D'Inzeo, T., Vella, A., De Luca, A., Tumbarello, M., Ricciardi, W., & Sanguinetti, M. (2015). Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre Yeast One over nine years at a large Italian teaching hospital. Antimicrob Agents Chemother, 59, 3944–3955.

Thareja, S., Verma, A., Kalra, A., Gosain, S., Rewatkar, P. V., & Kokil, G. R. (2010). Novel chromeneimidazole derivatives as antifungal compounds: Synthesis and in vitro evaluation. Acta Poloniae Pharmaceutica, 67(4), 423–427.

Verma, A., Joshi, S., & Singh, D. (2013). Imidazole: Having versatile biological activities. Journal of Chemistry, 12, 1–12.

Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2016). Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Frontiers in Microbiology, 7, 2173.

Xiao, M., Fan X., Chen, S. C., Wang, H., Sun, Z. Y., Liao, K., Chen, S. L., Yan, Y., Kang, M., Hu, Z. D., Chu, Y. Z., Hu, T. S., Ni, Y. X., Zou, G. L., Kong, F., & Xu, Y. C. (2015). Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. Journal Antimicrobial Chemotherapy, 70(3), 802–810.

Yakovychuk, N. D., Dejneka, S. Y., Sydorchuk, I. I., Sydorchuk, L. I., Humenna, A. V., & Bendas, V. V. (2017). Populyatsiynyy rivenʹ holovnoyi mikrobioty ta drizhdzhopodibnykh hrybiv rodu Candida v zhinok, yaki khvori na vulʹvovahinalʹnyy kandydoz [Population level of main microbiota and yeast-like fungi of genus Candida in women with vulvovaginal candidiasis]. Zaporizʹkyy Medychnyy Zhurnal, 19(3), 337–341 (in Ukrainian).

Zhang, S. L., Chang, J. J., Damu, G. L. V., Geng, R. X., & Zhou, C. H. (2013). Berberine azoles as antimicrobial agents: Synthesis, biological evaluation and their interactions with human serum albumin. Medicinal Chemistry Communications, 4, 839–846.

How to Cite
Yakovychuk, N. D., Deyneka, S. Y., Grozav, A. M., Humenna, A. V., Popovych, V. B., & Djuiriak, V. S. (2018). Аntifungal activity of 5-(2-nitrovinyl) imidazoles and their derivatives against the causative agents of vulvovaginal candidiasis. Regulatory Mechanisms in Biosystems, 9(3), 369-373. https://doi.org/https://doi.org/10.15421/021854